Riskpilot← Back to searchSign inGet full accessProSanis Sverige AB
ABActiveOrg 5592109069Tulegatan 6Traditional, complementary and alternative medicine activities · NACE 8696Est. 20192 employees
Revenue 2025
SEK 2,3M
+177% vs 2024
EBITDA margin
17.5%
+26% vs 2024
Equity ratio
63.2%
Financial strength
Net profit 2025
SEK 207K
-23% vs 2024
| Revenue | SEK 2,3M | +177% |
| EBITDA | SEK 407K | +26% |
| Net profit | SEK 207K | -23% |
| Total assets | SEK 1,2M | +78% |
| Equity | SEK 756K | +38% |
| Employees | 2 | — |
Legal name
ProSanis Sverige AB
Org number
5592109069
Legal form
Aktiebolag
NACE code
8696 · Traditional, complementary and alternative medicine activities
Founded
1 juli 2019
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva behandling, rehabilitering, förebyggande verksamhet och upplysning inom områdena fysisk, psykisk och social hälsa och därmed förenlig verksamhet.
Address
Tulegatan 6
Email
info@prosanis.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 732 | 697 | 517 | 839 | 2 323 |
| Staff expenses | — | −296 | −418 | −369 | −909 |
| EBITDA | 5 | 261 | −70 | 323 | 407 |
| Depreciation & amort. | −0 | — | — | — | −45 |
| EBIT | 5 | 261 | −70 | 323 | 362 |
| Net financials | — | 1 | 1 | 0 | 0 |
| Profit before tax | 5 | 262 | −70 | 323 | 267 |
| Tax | −2 | −54 | — | −53 | −59 |
| Net profit | 3 | 208 | −70 | 270 | 207 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 196 | 431 | 328 | 672 | 1 195 |
| Equity | 141 | 348 | 279 | 549 | 756 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 55 | 83 | 50 | 123 | 343 |
| Total debt | 55 | 83 | 50 | 123 | 343 |
EBITDA margin
17.5%
This company
15.8%
Market median
+11% vs market
20212025
Equity ratio
63.2%
This company
38.2%
Market median
+65% vs market
20212025
Return on equity
27.4%
This company
18.4%
Market median
+49% vs market
20212025
Net profit margin
8.9%
This company
8.1%
Market median
+10% vs market
20212025
Asset turnover
1.94×
This company
1.12×
Market median
+73% vs market
20212025
Debt / equity
0.58×
This company
0.62×
Market median
+6% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RR Chief Executive Officer | Chief Executive Officer | 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2026 | |
| Deputy Board Member | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ProSanis Sverige AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Renée Ruth Grundström Ekdahl | Chief Executive Officer | 0 companies |
| Karl Gustaf Ekdahl | Chairman | 0 companies |
| Sigrid Renèe Nga Wah Johnson | Deputy Board Member | 0 companies |